AAV‐mediated gene therapy improving mitochondrial function provides benefit in age‐related macular degeneration models.

Autor:	Millington‐Ward, Sophia, Chadderton, Naomi, Finnegan, Laura K., Post, Iris J.M., Carrigan, Matthew, Gardiner, Tom, Peixoto, Elisa, Maloney, Daniel, Humphries, Marian M., Stitt, Alan, Léveillard, Thierry, Humphries, Pete, Kenna, Paul F., Palfi, Arpad, Farrar, G. Jane
Předmět:	MACULAR degeneration PHOTORECEPTORS GENE therapy MITOCHONDRIA AEROBIC capacity COMPLEMENT factor H
Zdroj:	Clinical & Translational Medicine; Aug2022, Vol. 12 Issue 8, p1-7, 7p
Abstrakt:	Twenty-eight-hour post-transduction transduced cells and a minimum of 16 wells of untransduced cells were insulted with 5-mM NaIO3 and 12 h post-insult cells underwent a mitochondrial stress test using an XFe96 Seahorse. AAV-mediated gene therapy improving mitochondrial function provides benefit in age-related macular degeneration models AAV2/8-ophNdi-treated and NaIO3-insulted cells (K-O) were compared to untreated (A-E) and untreated and NaIO3-insulted cells (F-J). With an estimated 196 million people suffering from age-related macular degeneration (AMD) in 2020 and predicted to increase to 288 million by 2040,1 dry AMD, representing 70%-90% of AMD cases, represents an enormous clinical need with no current therapies. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.